IFCC实验室差错与患者安全工作组关于全球采纳实验室医学基本质量指标面板的建议
国际临床化学与检验医学联合会(IFCC)实验室差错与患者安全工作组通过多国专家共识会议,审阅IFCC质量指标模型(MQI)并筛选高优先级指标,最终确定并批准6项覆盖检验全流程的基本质量指标:申请标识错误率(Pre-MisR)与样本标识错误率(Pre-MisS)、样本拒收率(Pre-RejS)、溶血率(自动溶血指数Pre-HemI或肉眼检查Pre-HemV)、外部质量评估/能力验证不合格结果率(Intra-Unac)、急诊肌钙蛋白90百分位周转时间(Post-TnTAT、Post-TnTAT clin)以及错误实验室报告率(Post-RectRep)。建议还提供了计算、报告频率及纳入IFCC与国家比对方案的建议。该面板为标准化、可行的框架,有助于数据整合与国家及全球质量规范的制定,促进患者安全持续改进。
要点
- 6项基本质量指标覆盖检验全流程:申请与样本标识错误率、样本拒收率、溶血率、EQA/PT不合格率、急诊肌钙蛋白90百分位周转时间、错误报告率。
- 溶血检测可采用自动溶血指数(Pre-HemI)或肉眼检查(Pre-HemV)两种方式报告。
- 急诊肌钙蛋白周转时间以急诊室第90百分位(Post-TnTAT、Post-TnTAT clin)为报告指标。
- 建议提供了各指标的计算方法、报告频率及纳入IFCC与国家比对方案的具体建议。
- 该面板旨在支持纳入国家比对项目与IFCC MQI平台,促进数据整合与质量规范制定。
适用人群与场景
- 适用于医学实验室,覆盖检验全流程(检验前、检验中、检验后),包括急诊室肌钙蛋白检测场景。
诊断标准与关键阈值
- 基本质量指标面板共6项:申请标识错误率(Pre-MisR)与样本标识错误率(Pre-MisS);样本拒收率(Pre-RejS);溶血率,通过自动溶血指数(Pre-HemI)或肉眼检查(Pre-HemV)检测;外部质量评估/能力验证不合格结果率(Intra-Unac);急诊肌钙蛋白第90百分位周转时间(Post-TnTAT、Post-TnTAT clin);错误实验室报告率(Post-RectRep)。
处置流程与药物剂量
- 建议提供了各质量指标的计算方法、报告频率以及纳入IFCC与国家比对方案的建议。
研究设计与关键结果
- 通过共识会议,来自多个国家的专家审阅了IFCC质量指标模型(MQI)以识别高优先级指标,选择时优先考虑患者伤害概率、检测难易程度以及数据收集与在国家范围内实施的可行性。
- 确定并批准了6项覆盖检验全流程的基本质量指标:申请标识错误率(Pre-MisR)与样本标识错误率(Pre-MisS);样本拒收率(Pre-RejS);溶血率(自动溶血指数Pre-HemI或肉眼检查Pre-HemV);外部质量评估/能力验证不合格结果率(Intra-Unac);急诊肌钙蛋白第90百分位周转时间(Post-TnTAT、Post-TnTAT clin);错误实验室报告率(Post-RectRep)。
证据类型、等级与局限
- 证据类型:IFCC工作组基于共识会议提出的建议。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该基本质量指标面板为标准化且可行的框架,支持将其整合入国家比对方案与IFCC MQI平台。
- 实施该面板将促进数据整合,加强国家与全球质量规范的制定,并有助于患者安全的持续改进。
指南或共识出处
- IFCC实验室差错与患者安全工作组建议,发表于Clinical Chemistry and Laboratory Medicine(Clin Chem Lab Med)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To maximize participation in the international standardization effort, this recommendation aims to update the international guidance of the Working Group on Laboratory Errors and Patient Safety of the International Federation of Clinical Chemistry and Laboratory Medicine by identifying a limited and globally applicable panel of Essential Quality Indicators (QIs) focused on patient safety, clinical outcomes, and harmonization across medical laboratories.
METHODS: Through a consensus meeting, experts from multiple countries reviewed the IFCC Model of Quality Indicators (MQI) to identify high-priority indicators. Selection prioritized the probability of patient harm, ease of detection, and feasibility of data collection and implementation within national contexts.
RESULTS: Six essential QIs covering the total testing process were identified and ratified: (1) rate of misidentified requests (Pre-MisR) and misidentified samples (Pre-MisS); (2) rate of sample rejections (Pre-RejS); (3) rate of hemolysis detected either by automated hemolysis index (Pre-HemI) or visual inspection (Pre-HemV); (4) rate of unacceptable results in External Quality Assessment/Proficiency Testing (Intra-Unac); (5) turnaround time of cardiac troponin at the 90th percentile for the emergency room (Post-TnTAT, Post-TnTAT clin); and (6) rate of incorrect laboratory reports (Post-RectRep). Recommendations on calculation, reporting frequency, and integration into IFCC and national comparison programs are provided.
CONCLUSIONS: The proposed essential QI panel provides a standardized and feasible framework to support its integration into national comparison programs and the IFCC MQI platform. Its implementation will facilitate data consolidation, strengthen the development of national and global quality specifications, and contribute to continuous improvement in patient safety.
参考来源
- De Guire V, Galoro CAO, Ibarz M, et al. Recommendations from the IFCC Working Group on Laboratory Errors and Patient Safety for the Global Adoption of an Essential Quality Indicators Panel in Laboratory Medicine. Clin Chem Lab Med. 2025. PMID: 41259049. doi:10.1515/cclm-2025-1462
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。